New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
05:53 EDTQUREuniQure, Medison sign Glybera distribution agreement for Israel
uniQure N.V. and Medison Pharma announced an exclusive distribution agreement under which Medison will market Glybera, uniQure's gene therapy product for the treatment of lipoprotein lipase deficiency, or LPLD, in Israel and the Palestinian Authority. Medison will also be responsible for obtaining regulatory approval for Glybera in both territories. Financial terms of the agreement have not been disclosed. Glybera is approved in the EU as a treatment for LPLD, a potentially life-threatening, orphan metabolic disease that results in patients' inability to process fat in the blood after a meal.
News For QURE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 14, 2015
08:38 EDTQUREuniQure and Treeway to develop Amyotrophic Lateral Sclerosis therapy
uniQure and Treeway B.V., founded by entrepreneurs Bernard Muller and Robbert Jan Stuit, both diagnosed with Amyotrophic Lateral Sclerosis, have announced a collaboration with to develop a gene therapy treatment for ALS. uniQure has granted Treeway an exclusive license in this field to uniQure's relevant AAV5 viral vector and GDNF intellectual property. Treeway is responsible for the preclinical and clinical development of the ALS gene therapy treatment. uniQure will provide Treeway with its manufacturing capabilities and will further collaborate with Treeway on ALS gene therapy development. Treeway and uniQure will jointly commercialize any resulting ALS gene therapy with defined geographical rights for commercialization assigned to each company. Financial details of the agreement have not been disclosed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use